Rhumbline Advisers Raises Holdings in Roche Holding AG $RHHBY

Key Points

• Rhumbline Advisers has increased its holdings in Roche Holding AG by 7.4%, now owning 107,252 shares valued at approximately $4.4 million.
• Other institutional investors have also entered positions in Roche, with notable investments including Beck Mack & Oliver LLC and Corient IA LLC, both acquiring stakes worth upwards of $200,000.
• Roche's stock is currently trading at $41.35, reflecting a decline of 1.7%, with a 12-month high of $44.31.

Rhumbline Advisers increased its position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 107,252 shares of the company's stock after acquiring an additional 7,374 shares during the quarter. Rhumbline Advisers' holdings in Roche were worth $4,413,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Beck Mack & Oliver LLC purchased a new position in Roche in the 1st quarter valued at approximately $232,000. Corient IA LLC purchased a new position in shares of Roche in the first quarter valued at $616,000. FCA Corp TX bought a new stake in shares of Roche during the 1st quarter valued at $494,000. Atlas Capital Advisors Inc. purchased a new stake in Roche during the 1st quarter worth about $140,000. Finally, Everett Harris & Co. CA purchased a new stake in Roche during the 1st quarter worth about $445,000.

Roche Stock Down 1.7%

Shares of RHHBY opened at $41.35 on Monday. Roche Holding AG has a twelve month low of $34.10 and a twelve month high of $44.31. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 0.85. The business's 50-day moving average price is $40.33 and its 200-day moving average price is $40.35.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.